36m agoSeeking AlphaBEARISH 24General
Sagimet Biosciences stock rises after pricing $115M securities offering
Sagimet Biosciences (SGMT) prices $115M equity offering at $10/share plus pre-funded warrants; learn terms, expected Oct.
Why Is SAGIMET BIOSCIENCES Series A (SGMT) Stock Moving Today?
By the Top Tier Newswire AI Desk · reviewed against 7 wire stories
SAGIMET BIOSCIENCES Series A (SGMT) is drawing unusual attention today. Our newswire has captured 7 stories on SGMT across 6 sources in the last 36 hours, with AI sentiment reading mixed (avg 45/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
The written analysis for SGMT publishes to the public page once it clears the 4-hour delay. The coverage, sentiment and session data below are already here.
SGMT by the numbers
Coverage: 7 stories / 6 sourcesAI sentiment: 45/100 (mixed)
The headlines behind the move
42m agoThe FlyBEARISH 28General
Sagimet Biosciences prices 8.75M shares at $10.00 in underwritten offering
46m agoThe FlyBULLISH 59Product/PR
Sagimet Biosciences reports results from Phase 3 ASC40-304 OLE clinical trial
49m agoBusiness InsiderBEARISH 24General
Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
FOSTER CITY, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways,...
58m agoSEC 8-KNEUTRAL 50General
Sagimet Biosciences Inc. (SGMT) files 8-K
Filed: 2026-09-30 AccNo: 0001193125-26-408224 Size: 11 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
1h agoStockTitanBULLISH 67Product/PR
Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026
2d agoGlobeNewswireBULLISH 63Product/PR
Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026
FOSTER CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that...
Frequently asked questions
Why is SGMT stock moving today?
SAGIMET BIOSCIENCES Series A (SGMT) is drawing unusual attention today. Our newswire has captured 7 stories on SGMT across 6 sources in the last 36 hours, with AI sentiment reading mixed (avg 45/100). The most recent driver: "Sagimet Biosciences stock rises after pricing $115M securities offering" (Seeking Alpha).
Is SGMT a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of SGMT coverage reads 45/100 over 7 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More moves explained today
- Why is QURE down today (-37.33%)
- Why is IOVA up today (+31.48%)
- Why is FICO down today (-26.52%)
- Why is CCL up today (+13.41%)
- Why is PWP up today (+11.82%)
- Why is WRBY up today (+11.39%)
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on SGMT: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.